Biofrontera Inc. (BFRI) stock

BFRINasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BFRIW

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 9/30

$0.93−0.01 (-1.24%)

Close on Nov 12, 2026Market cap $13.75MP/E –Yield –

Biofrontera ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

For fiscal 2025 it was -$11.21M.

Period	Period end	Value	Change
FY2025	Dec 31, 2025	-$11.21M	–
FY2024	Dec 31, 2024	-$16.79M	–
FY2023	Dec 31, 2023	-$22.08M	–

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q2 FY2026	Jun 30, 2026	-$459.00K	–
Q1 FY2026	Mar 31, 2026	-$4.27M	–
Q2 FY2025	Jun 30, 2025	-$5.05M	–
Q1 FY2025	Mar 31, 2025	-$4.52M	–

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is BFRI.

Revenue growth17.8% · median 15.5%

Operating margin-14.2% · median -42.9%

Net margin-13.8% · median -7.3%

Advertisement
300 × 250

See a number that looks wrong?